-

07:36:52 AM

ALVO Stock News

ALVO - Alvotech

03/28/23 5:00 AM

Nasdaq : ALVO

Alvotech Provides Update on Corporate Sustainability Framework

Alvotech (Nasdaq: ALVO) (the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced an update to the Company’s Corporate Sustainability framework, including the release of key environmental, social and

RHEA-AI

neutral

03/17/23 9:10 AM

Nasdaq : ALVO

conferencesclinical trial

Alvotech to Present Clinical Study Data for AVT04, a Proposed Biosimilar to Stelara®, at 2023 American Academy of Dermatology (AAD) Annual Meeting

Alvotech to present two posters related to pharmacokinetics and confirmatory clinical studies for AVT04 (ustekinumab), a proposed biosimilar to Stelara® Marketing applications for AVT04 have been submitted in major markets including U.S. and Europe Alvotech ( NASDAQ: ALVO ), a global biotech

RHEA-AI

neutral

03/01/23 4:30 PM

Nasdaq : ALVO

earnings

Alvotech Reports Financial Results for Full Year 2022 and Provides Business Update

Full year 2022 total revenue, including other income, increased by 114% to $85.0 million, compared to $39.7 million in 2021, driven by both milestone revenue and product revenue from commercialization of AVT02, a biosimilar to Humira ®, in 17 countries Three biosimilar candidates, AVT03 (Prolia ®

RHEA-AI

neutral

02/27/23 7:15 PM

Nasdaq : ALVO

earnings

Alvotech Announces Webcast of 2022 Full Year Financial Results at 8:00 am ET on March 2, 2023

Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today that it will release financial results for full year 2022, after U.S. markets

RHEA-AI

neutral

02/14/23 4:01 PM

Nasdaq : ALVO

Updated market making agreement with Landsbankinn for Alvotech shares trading on the Nasdaq Iceland market

Alvotech (Nasdaq: ALVO) and Landsbankinn hf. have updated their market making agreement, which has been in effect since Alvotech’s shares were admitted to trading in Iceland on June 23, 2022. The updated agreement goes into effect at the start of trading on the Nasdaq Iceland market on February 15,

RHEA-AI

neutral

02/10/23 4:01 PM

Nasdaq : ALVO

Settlement of Alvotech Private Share Placement Completed

Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today the completion of the equity transaction announced on January 23, 2023 (the

RHEA-AI

neutral

02/09/23 2:30 AM

Nasdaq : ALVO

EMA Confirms Acceptance of Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab)

Partners Alvotech and STADA have marketing authorization application (MAA) for ustekinumab accepted for filing by the European Medicines Agency (EMA) EMA opinion on AVT04 could come as soon as the second half of 2023 Reference product Stelara ® (ustekinumab) is prescribed to treat a variety of

RHEA-AI

very positive

02/06/23 4:00 AM

Nasdaq : ALVO

Alvotech enters into commercialization agreement with Advanz Pharma for proposed biosimilar to Xolair® (omalizumab)

Advanz Pharma will commercialize AVT23, a proposed biosimilar to Xolair® (omalizumab) in the European Economic Area, UK, Switzerland, Canada, Australia, and New Zealand Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for

RHEA-AI

very positive

01/24/23 4:00 AM

Nasdaq : ALVO

Alvotech and Bioventure Announce Approval of AVT02 (adalimumab) as Simlandi in Saudi Arabia

AVT02 as Simlandi™ is the first biosimilar approved under the strategic partnership between Alvotech and Bioventure Alvotech (NASDAQ: ALVO) and Bioventure, a wholly owned subsidiary of GlobalOne Healthcare Holding LLC (“GHH”), the healthcare division of Yas Holding LLC, today announced that the

RHEA-AI

very positive

01/23/23 3:01 AM

Nasdaq : ALVO

Alvotech Completes $137 Million Private Share Placement

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the completion of a private placement of approximately $137 million, at current exchange rates, of its ordinary shares, par value $0.01

RHEA-AI

neutral

1 2 3 4 5 6 Next